WES of melanoma tumours prior to combined immune checkpoint blockade treatment.

• DS DUO:0000007 (version: 2019-01-07)disease specific researchThis data use permission indicates that use is allowed provided it is related to the specified disease.ModifiersHP:0002664
• RU DUO:0000014 (version: 2019-01-07)research use onlyThis data use limitation indicates that use is limited to research purposes (e.g., does not include its use in clinical care).
• NPUNCU DUO:0000018 (version: 2019-01-07)not for profit, non commercial use onlyThis data use modifier indicates that use of the data is limited to not-for-profit organizations and not-for-profit use, non-commercial use.
• US DUO:0000026 (version: 2019-01-07)user specific restrictionThis data use modifier indicates that use is limited to use by approved users.
• IS DUO:0000028 (version: 2019-01-07)institution specific restrictionThis data use modifier indicates that use is limited to use within an approved institution.

Requests for data access for research purposes only will be made to the relevant Data Access Committee contact and proceed in accordance with the generic agreement between the data Provider and the data Recipient as outlined herein.

DATA ACCESS AGREEMENT This Data Access Agreement (“Agreement”), effective as of the ____ day of _________________, 20__ (“Effective Date”), is by and between The University of Texas M. D. Anderson Cancer Center, an institution of The University of Texas System and an agency of the State of Texas, with an address at 1515 Holcombe Boulevard, Houston, Texas 77030 (“Provider”), and _____________ (“Recipient”) on behalf of its investigator _____________ (“Recipient Investigator”) (collectively, the “Parties”; each, a “Party”). RECITALS Provider maintains the following de-identified data in the European Genome-phenome Archive (EGA) managed by the European Bioinformatics Institute (“Data”); Accession EGAS00001003857: WES of melanoma tumors treated with combined immune checkpoint blockade. This dataset contains 52 whole exome sequencing files being paired normal (peripheral blood mononuclear cell) and tumor WES data and associated phenotype metadata from 26 patients with advanced melanoma who were subsequently treated with combined anti-CTLA-4 and anti-PD-1 checkpoint blockade immunotherapy. Included data are from pre-treatment samples. and Provider is willing to allow Recipient to access such Data from the EGA for the internal non-commercial research purposes of (“Purpose”); Use of the data is reserved for Non-Profit Institutions only and all findings must be made available to the public and available to the larger scientific community. Allowable Research Projects must be for cancer-related research. pursuant to the terms of this Agreement. In consideration of the mutual promises and covenants herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 1. The Data will be used solely for the Research by Recipient Investigator and personnel under his immediate supervision at Recipient and may not be transferred to any other investigator or to any third party without prior written permission from Provider. The Material may not be used for any purpose other than the Research, including without limitation for any commercial purpose or for research in human subjects (including, without limitation, in diagnostic testing). 2. Neither Recipient nor Recipient Investigator shall disclose Data to any person or party other than the Recipient Investigator hereunder without Provider’s prior written consent. 3. The Data will be used in compliance with all applicable laws, regulations, and guidelines applicable to the Data, including without limitation any applicable export controls. 4. In any publication resulting from use of the Data, Recipient and Recipient Investigator shall acknowledge ______________ (“Provider Investigator”) and Provider as the provider of the Data. 5. This Agreement shall be effective as of the Effective Date and shall remain effective until completion of the Research. Either Party may terminate this Agreement with or without cause upon thirty (30) days’ written notice to the other Party. Upon expiration or termination of this Agreement for any reason, Recipient shall destroy all Data received pursuant to this Agreement. 6. Any notice permitted or required as provided for herein shall be in writing and to the contact and address as noted below or as may be provided by either party to the other in writing from time to time.   Notice to Provider shall be to: Chief Legal Officer The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd., Unit 1674 Houston, Texas 77030 Phone: 713-745-6633; Facsimile: 713-745-6029 With a copy to: The University of Texas M. D. Anderson Cancer Center 1515 Holcombe Blvd., Unit 1676 Office of Research Administration Attn: AVP, Research Administration Houston, TX 77030 Phone: 713-792-3672; Facsimile: 713-792-7455 Notice to Recipient shall be to: __________________________ __________________________ __________________________ __________________________ __________________________ 7. In the event Protected Health Information (“PHI”), as defined by the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), as amended, is inadvertently created, accessed by, and/or disclosed to Recipient in connection with this Agreement, Recipient will immediately notify the Provider and will return to Provider or destroy such PHI, in accordance with the Provider’s instructions. Pending return or destruction of any PHI, Recipient shall maintain the confidentiality of all Data (including the PHI) and use appropriate safeguards to prevent access to, use, or disclosure of Data (including the PHI). 8. PROVIDER MAKES NO REPRESENTATION OR WARRANTY CONCERNING THE MATERIAL, INCLUDING WITHOUT LIMITATION, WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. 9. Recipient Investigator and Recipient accept all liability for any use of the Data and for any loss, claim, or damage which may arise from or in connection with this Agreement or the use, handling or storage of the Data and in no event shall Provider or Provider Investigator be liable for any such use, loss, claim or damage. 10. This Agreement is via EGA mechanism.   [Insert Recipient Name Here] THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER By: By: Name: Name: Title: Title: Date: Date: Read and Understood: Read and Understood: Recipient Scientist: Provider Scientist: Name: Name: Title: Title: Date: Date: